Archive for ‘arthroscopy’

LEVL Measures Acetone in Breath to Detect Body Fat Burning

LEVL Measures Acetone in Breath to Detect Body Fat Burning

levl

 

levl-parts

 

Medamonitor, a division of GM Nameplate, a Seattle, WA company, received FDA Class I certification for its LEVL acetone breath testing device. Designed for detecting how well your body burns fat, rather than forindirect blood glucose testing, the device relies on studies showing a correlation between exhaled acetone and burned body fat. This can be an important indicator, as body weight can vary due to changes in water and muscle content, in addition to fat. Those wishing to lose body fat, rather than muscle mass or water, would be able to detect whether their diet and exercise regimen is doing the trick.

The device includes a couple pods into which breaths are deposited and then placed into the main unit’s testing port. The front of the unit will then display a “LEVL score” between 1 and 6, and the reading will also be synced with the accompanied smartphone app. Scores 2 and higher mean an elevated level of acetone, pointing to the body burning fat as expected.

Medamonitor promises to give an update on the price and availability of the LEVL early next year. For now here’s a promo video from the company introducing the LEVL:

Flashback: Portable Acetone Detector to Help Monitor Fat Burning During Exercise…

Product page: LEVL…

Via: Medamonitor…

Full story

United States Painless Lancet Market – Growth, Share, Opportunities, Competitive Analysis and Forecast Report 2016

United States Painless Lancet Market – Growth, Share, Opportunities, Competitive Analysis and Forecast Report 2016

logo447

 

Description

Notes:
Sales, means the sales volume of Painless Lancet
Revenue, means the sales value of Painless Lancet

Get sample report at @ :https://marketreportscenter.com/request-sample/479718

This report studies sales (consumption) of Painless Lancet in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering
Sarstedt
Owen Mumford
Medline
Nipro Corporation
Accriva Diagnostics
Arkray Usa
Bayer Healthcare
Medicore
Medipurpose
Sterilance
Narang Medical Limited
LifeScan

Browse full report with TOC @ : https://marketreportscenter.com/reports/479718/united-states-painless-lancet-market-report-2016

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into
Type I
Type II
Type III
Split by applications, this report focuses on sales, market share and growth rate of Painless Lancet in each application, can be divided into
Application 1
Application 2
Application 3

Receive discount on report at @ : https://marketreportscenter.com/request-discount/479718

Media contacts:
Sam Collins
Market Reports Center
Call : 1-646-883-3044 (US)
Email : info@marketreportscenter.com
visit our website : https://marketreportscenter.com

Full story

IRadimed’s MRI Compatible MRidium 3860+ IV Infusion Pump FDA Cleared

IRadimed’s MRI Compatible MRidium 3860+ IV Infusion Pump FDA Cleared

iradimed-pump

 

IRadimed, a company out of Winter Springs, Florida, won FDA clearance for its MRidium 3860+ MRI-compatible IV infusion pump. The device has non-magnetic motor and no ferrous (containing iron) components that would be affected by a magnetic field. It’s safe to use around MRI machines up to 3.0 Tesla, which means just about any scanner found inside a hospital.

mridiumThe device can pump doses from 0.1 mL to 1,400 mL per hour, and so can be used with pediatric and adult patients that may need very different infusion rates.

Thanks to a built-in lithium battery, the device can be self-powered for up to 12 hours at 125 mL per hour.

  • World’s ‘Only’ Non–Magnetic IV Infusion Pump
  • Placement up to the 10,000 Gauss Line
  • Intuitive Smart IV Pump technology reduces field errors
  • Expandable to a second infusion channel
  • Masimo™ SpO2 Patient Monitoring
  • Large 10-Numeric Keypad – Quick Programming
  • Infusion Range – 0.1 to 1400 mL/Hr
  • Over 12–Hour Battery at 125mL/Hr
  • Adjustable KVO Rate
  • Upstream / Downstream Occlusion Detection
  • Air-in-Line Detection
  • Delivery via Syringe, Bag or Bottle

Product page: MRidium 3860+…

Via: IRadimed…

Full story

Measuring Blood Flow from Conventional Color Doppler Ultrasound

Measuring Blood Flow from Conventional Color Doppler Ultrasound

blood-flow-from-ultrasound

 

Measuring intravascular blood flow is currently only possible with invasive methods. Swiss researchers from École polytechnique fédérale de Lausanne (EPFL) and Geneva University Hospital decided to see whether color Doppler ultrasound data holds enough information to derive the velocity of blood flowing through a vessel. They created a mathematical model of the vessels and blood within, and how ultrasound interacts with them. The results are pretty impressive, though not accurate enough for clinical use, and point to the possibility of one day getting accurate blood flow gauging from existing hardware.

Here’s a video of the software processing color Doppler data from a conventional clinical ultrasound transducer:

Link to study: A feasability study of color flow doppler vectorization for automated blood flow monitoring…

More info: Automated Blood Flow Monitoring from Color Flow Doppler Vectorization…

Full story

Abbott’s i-STAT Alinity Bedside Blood Testing System Approved for Sale in Europe

Abbott’s i-STAT Alinity Bedside Blood Testing System Approved for Sale in Europe

Abbott won European CE Mark approval for its i-STAT Alinity blood testing system. It’s a portable point-of-care device that can be used to test for a variety of metabolites, including blood chemistries and cardiac biomarkers. It works off of only two or three drops of blood and displays results within ten minutes, depending on the assay used.

 

alinity

It has a touchscreen display as the interface and includes a camera for barcode tracking of samples and results.

Some of the i-STAT Alinity’s features according to the announcement:

  • Expansive testing menu capabilities to enable the most combinations of tests in a single cartridge and new types of tests in the future, including tests for brain injury, infectious disease and oncology
  • Advanced quality control features designed with patient safety and regulatory compliance in the forefront
  • Wireless or hard-wired connectivity so healthcare providers can manage diagnostic data and oversight with the broader healthcare system’s network
  • Cloud connectivity that uses a standard web browser, making it easy for health systems to customize multiple i-STAT Alinity instruments and provide seamless transmission of quality control data
  • A large, bright, color touchscreen with graphics-driven, on-screen guidance and advanced light and sound notifications that alert clinicians with critical information
  • An ergonomic design with easy-grip handling that is balanced, comfortable and secure
  • Durable materials designed to prevent damage from drops and harsh cleaning substances commonly used in clinical settings

Product page: i-STAT Alinity System…

Via: Abbott…

Full story

Semprus BioSciences to develop surface-modified endotracheal tube

Semprus BioSciences to develop surface-modified endotracheal tube

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced that Semprus BioSciences, a wholly owned subsidiary of Teleflex Incorporated, has been awarded the initial phase of a $2.3 million research grant from the U.S. Army’s Telemedicine and Advanced Technology Research Center (TATRC), located at Fort Detrick, MD. The award will support research and development of a surface-modified endotracheal tube that combines the Semprus Sustain™ Technology with the delivery of antimicrobials.

The research will be conducted at Semprus’ facilities in Cambridge, MA, in conjunction with U.S. Army Institute for Surgical Research (USAISR) at Fort Sam Houston in San Antonio, TX. This award builds upon an initial $1 million TATRC grant awarded to Semprus BioSciences in 2011 to develop the world’s first orthopedic devices designed to reduce biofilm formation.

“We are pleased to be working with the U.S. Army to help resolve a most critical issue affecting our wounded men and women in combat,” said Benson Smith, Chairman, President and CEO of Teleflex. “This award was catalyzed by the U.S. Army’s positive review of data from our prior award, and we are equally hopeful that this collaboration will yield greatly improved clinical outcomes for soldiers, as well as substantial cost savings to the U.S. military and civilian health care systems.”

Patients who require respiratory support are typically connected to a ventilator with an endotracheal tube that is inserted in the throat. In intensive care units (ICUs), where patients are ventilated for extended periods of time, bacterial adherence to the endotracheal tube is considered the first step in developing a lung infection, or ventilator-associated pneumonia (VAP).

Although VAP is common in civilian hospital ICUs – with rates as high as 16 cases per 1,000 ventilator days – it is a larger problem in combat military hospitals ICUs with 9.7 to 60.6 cases per 1,000 ventilator days. Late-onset VAP is associated with a mortality rate of up to 65% and more than $60,000 in increased cost per patient.

“Bacterial attachment and proliferation on endotracheal tubes is a contributing factor in the occurrence of VAP in ICU patients,” said David L. Lucchino, co-founder and Vice President of Semprus BioSciences. “Through the combined materials approach of the Semprus Sustain Technology and antimicrobial drug release, we expect to reduce bacterial colonization and biofilm formation on the surface of endotracheal tubes which should affect the incidence of VAP.”

Source :http://www.news-medical.net/news/20121109/Semprus-BioSciences-to-develop-surface-modified-endotracheal-tube.aspx

Full story

Direct Flow Medical Transcatheter Aortic Valve Does Well in Clinical Study

Direct Flow Medical Transcatheter Aortic Valve Does Well in Clinical Study

Direct Flow Medical Transcatheter Aortic Valve Does Well in Clinical Study

The Direct Flow Medical (DFM) percutaneous aortic valve is designed to have the performance (function, durability and safety) of a surgical valve while incorporating the desirable attributes for transcatheter delivery with the additional ability to be positioned, repositioned and completely retrieved if necessary.

dfm valve

The bovine pericardial leaflets are attached to an inflatable polyester fabric cuff which conforms to the native aortic valve annulus and left ventricular outflow tract to form a seal to minimize the potential of paravalvular leak. The implant is designed with independently inflatable ventricular and aortic rings, which encircle and capture the native valve annulus to provide positive axial anchoring of the device. Inflation of the cuff with a saline and contrast solution renders the valve immediately functional and permits fluoroscopic visualization. Before final deployment, the saline and contrast mixture is exchanged under pressure, maintaining cuff shape and position, with a solidifying inflation media (IM) that hardens to form the permanent support structure.

Direct Flow Medical (Santa Rosa, CA) reported initial results of a clinical study of its Transcatheter Aortic Valve System that met its primary mortality endpoint and that “greater than 95 percent of patients had mild or less aortic regurgitation, and no patients experienced vascular complications.”

Direct Flow Medical valve Direct Flow Medical Transcatheter Aortic Valve Does Well in Clinical Study

The valve is made of a polymer frame, bovine pericardium leaflets, and two inflatable rings that sit on both sides of the patient’s own valve, completely taking over its space. Because the rings can deflate as well, the valve can be easily repositioned for a better fit or removed if complications occur.

Some of the findings reported from the study:

The DISCOVER Trial is a prospective, multicenter study of up to 100 patients conducted at 10 European sites of patients with severe aortic valve stenosis who require replacement of their native aortic valve but are at extreme risk for open surgical repair. The device studied was the Direct Flow Medical Transcatheter Aortic Valve System, which is endovascularly delivered via an 18F introducer sheath. The trial was initiated in November 2011 and the first patient was treated at the L’Institut Jacques Cartier in Massy, France by Co-Principal Investigator Thierry Lefevre, MD.

Direct Flow Medical v Direct Flow Medical Transcatheter Aortic Valve Does Well in Clinical StudyIn the presentation of 30 day results for the pre-specified CE Cohort of 33 patients reported by Co-Principal Investigator Joachim Schofer, MD from the Medical Care Center, Hamburg, Germany, all patients were successfully treated via a transfemoral approach using the low profile, flexible Direct Flow Delivery System. The primary endpoint, freedom from all-cause mortality from procedure to 30 days, was met at 97 percent. Freedom from all cause cardiovascular mortality at 30 days was 100 percent.

Importantly, the Direct Flow Valve resulted in 97 percent mild or less aortic regurgitation, with 81 percent of patients experiencing none/trace aortic regurgitation as reported by the study Corelab. There were no major vascular complications in any patients post-procedure through 30 days even though the minimum vessel diameter treated in the study was 5.2 mm. The mean gradient pre-procedure to discharge and out to 30 days of 46.0, 13.6 and 12.9 mmHg, respectively, demonstrated the ability to significantly reduce gradients over time. All hemodynamic results were analyzed by an independent imaging core laboratory.

Source : http://www.directflowmedical.com/valve.html

Full story

ARGO’s Rewalk Technology on Display at Advamed

ARGO’s Rewalk Technology on Display at Advamed

ARGO’s Rewalk Technology on Display at Advamed

Argo Medical Technologies Ltd. does far more than restore mobility to people with severe walking impairments. By enabling wheelchair users to stand, walk, and climb stairs, we restore upright mobility, quality of life, health, inclusion, and more.

Argo brings mobility face-to-face with society. ReWalk™, the first commercially available upright walking technology, enables wheelchair users with lower-limb disabilities to stand, walk, and even climb stairs. For potentially hundreds of thousand of wheelchair users, ReWalk™ delivers a new perspective – on the world, on themselves, and on life.

ReWalk™ is an alternative mobility solution to the wheelchair for individuals with severe walking impairments, enabling them to stand, walk, ascend/descent stairs and more.

ReWalk™ is a new realization of the powered exoskeleton concept and provides user-initiated mobility; it consists of a light wearable brace support suit, which integrates actuation motors at the joints, an array of motion sensors, a computer system based on sophisticated control and safety algorithms and tailored rechargeable batteries.

ReWalk™ enables people with lower limb disabilities such as Spinal Cord Injury (SCI) and Spina Bifida to carry out routine ambulatory functions. ReWalk™ restores a person’s mobility functions, thus improving both quality of life and physical health. ReWalk™ promises to dramatically reduce the need for physical therapy and re-hospitalization that occur due to immobility-related complications in individuals with severe walking impairments.

ReWalk™ is a man-machine device where the user is actively involved and has control of all mobility functions, through unique control processes. Walking is controlled through subtle changes in center of gravity, stability and safety are secured by use of crutches.

Participation in mobility control comes naturally and intuitively, and brings tangible health and emotional benefits. ReWalk™ is not just a vertical wheelchair – ReWalk™ restores the element of control over mobility so lacking for wheelchair users.

As any wheelchair user can attest, life in a wheelchair carries a hefty healthcare price tag. Serious problems with the urinary, respiratory, cardiovascular and digestive systems are common, as well as osteoporosis, pressure sores and other afflictions.

By maintaining users upright on a daily basis, and exercising even paralyzed limbs in the course of movement, ReWalk™ alleviates many of the health-related problems associated with long-term wheelchair use. In addition to relieving suffering, this has a real impact on healthcare costs – cutting, and enabling both insurers and individuals to redirect funds to other avenues.

Adoption of ReWalk™ by wheelchair users results in significant cost saving at both institutions and private homes. ReWalk™ makes standing devices, stair lifts, bed lifts, and other mobility assistance apparatus redundant. Similarly, ReWalk™ users don’t require expensive powered wheelchairs – or the oversize vehicles and devices required to handle them. With ReWalk™, users require only minimal additional mobility assistance – dramatically increasing independence together with cost saving on a yearly basis.

Functionality:

All day usage

Mobility – walking, sitting-to-standing, standing-to-sitting, ascending/descending stairs and slopes

Training – replacing other training equipment at home and at rehabilitation center

Prerequisites:

Ability to use hands and shoulders (walking with crutches)

Healthy cardiovascular system and bone density

Claire Lomas, a paraplegic woman from Leicestershire in the UK, is making medical history as the world’s first person to use an exoskeleton for daily living around her home. Claire Lomas ReWalk Argo ReWalk Exoskeleton Now Ready to Take Home, Around Neighborhood (video)She proved the capability of the ReWalk system from ARGO Medical (Yokneam Ilit, Israel) by using it to walk a complete marathon and then lighting the Paralympic cauldron in Trafalgar Square.

Until now, the ReWalk was exclusively used in rehabilitation clinics with a therapist spotting the patient and providing constant step-by-step guidance. Now Claire is able to use the device independently, even walking up and down stairs and around the neighborhood. Though the ReWalk is slower on flat surfaces compared to a wheelchair, the psychological benefit of being able to get around house, stand upright and talk to people eye-to-eye is difficult to measure.

According to Larry Jasinski, CEO of Argo Medical, “Years of research and hard work from a very talented team of engineers has made this product possible. We’re looking forward to seeing Claire build on her accomplishments alongside the Cyclone team, whose training is such a key component in ensuring that users get the most from the device. We are officially launching the ReWalk personal use system in the EU with this start in the UK. It’s our aim to get as many individuals as possible walking again, and the launch of the ReWalk will allow customers to use the technology for a range of activities. It truly is the beginning of Rewalking as a part of daily life.”

Source : http://www.argomedtec.com/products.asp

Full story

Abbott’s Absorb Bioresorbable Vascular Scaffold Launched Internationally

Abbott’s Absorb Bioresorbable Vascular Scaffold Launched Internationally

Abbott’s Absorb Bioresorbable Vascular Scaffold Launched Internationally

Abbott Announces International Launch of the Absorb™ Bioresorbable Vascular Scaffold

World’s First Drug Eluting Bioresorbable Vascular Scaffold has Potential to Revolutionize Treatment of Coronary Artery Disease

Absorb Now Available in More Than 30 Countries Across Europe and Parts of Asia Pacific and Latin America

Clinical Data and Initial Commercial Experience Reinforce Broad Clinical Benefit of Absorb

September 25, 2012

Abbott Park, Illinois (NYSE: ABT) — Abbott announced today that Absorb™, the world’s first drug eluting bioresorbable vascular scaffold (BVS), is now widely available across Europe and parts of Asia Pacific and Latin America. Absorb is a first-of-its-kind device for the treatment of coronary artery disease (CAD). It works by restoring blood flow to the heart similar to a metallic stent, but then dissolves into the body, leaving behind a treated vessel that may resume more natural function and movement because it is free of a permanent metallic stent. Absorb is made of polylactide, a naturally dissolvable material that is commonly used in medical implants such as dissolving sutures.

 

The potential long-term benefits of a scaffold that dissolves are significant. The vessel may expand and contract as needed to increase the flow of blood to the heart in response to normal activities such as exercising; treatment and diagnostic options are broadened; the need for long-term treatment with anti-clotting medications may be reduced; and future interventions would be unobstructed by a permanent implant.

“This innovation represents a true paradigm shift in how we treat coronary artery disease. With the launch of Absorb, a scaffold that disappears after doing its job is no longer a dream, but a reality,” said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, the Netherlands. “Patients are excited about Absorb since it may allow blood vessels to return to a more natural state and expand long-term diagnostic and treatment options.”

The international launch of Absorb is supported by a robust clinical trial program that encompasses five studies in more than 20 countries around the world. Study data indicate that Absorb performs similar to a best-in-class drug eluting stent across traditional measures such as major adverse cardiovascular events (MACE) and target lesion revascularization (TLR), while providing patients with the added benefits associated with a device that dissolves over time. As the Absorb scaffold dissolves, vascular function is potentially restored to the blood vessel, allowing more blood to flow through the vessel as the body requires.

“Absorb is a leading example of Abbott’s dedication to advancing patient outcomes through innovative technology. Abbott has remained committed to meeting the growing physician and patient demand for a bioresorbable vascular scaffold – from the initial device developed nearly 10 years ago to the expansion of our manufacturing capabilities to support this international launch,” said John M. Capek, executive vice president, Medical Devices, Abbott. “We are proud to be the first company to commercialize a drug eluting bioresorbable vascular scaffold, which has the potential to revolutionize the way physicians treat their patients with coronary artery disease.”

Heart disease is the leading cause of death for men and women around the world, and CAD is the most common type of heart disease.1,2 CAD occurs when arteries that supply blood to the heart become narrowed or blocked, leading to chest pain or shortness of breath and increased risk of heart attack.

About the Absorb Bioresorbable Vascular Scaffold

Absorb is now available in a broad size matrix to support the needs of physicians treating patients with CAD.

The Absorb bioresorbable vascular scaffold, similar to a small mesh tube, is designed to open a blocked heart vessel and restore blood flow to the heart. Absorb is referred to as a scaffold to indicate that it is a temporary structure, unlike a stent, which is a permanent implant. The scaffold provides support to the vessel until the artery can stay open on its own, and then dissolves naturally. Absorb leaves patients with a vessel free of a permanent metallic stent and may allow the vessel to resume more natural function and movement, enabling long-term benefits.3,4

Abbott’s BVS delivers everolimus, an anti-proliferative drug used in Abbott’s XIENCE coronary stent systems. Everolimus was developed by Novartis Pharma AG and is licensed to Abbott by Novartis for use on its drug eluting vascular devices. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

Absorb is neither approved nor authorized for sale and currently is in development with no regulatory status in the United States. Absorb is authorized for sale in CE Mark countries. Absorb is now available in Europe, the Middle East, parts of Asia Pacific, including Hong Kong, Singapore, Malaysia and New Zealand, and parts of Latin America.

About Abbott Vascular

Abbott Vascular is the world’s leader in drug eluting stents. Abbott Vascular has an industry-leading pipeline and a comprehensive portfolio of market-leading products for cardiac and vascular care, including products for coronary artery disease, vessel closure, endovascular disease and structural heart disease.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

Back in 2006 when we first started to report on Abbott‘s development of bioresorbable stents, we were quite optimistic. Now a representative for the company is telling us that Abbott has finally received European approval for the ABSORB stent, a device that eventually frees the vessel to be in its almost natural, pulsating and re-endothelialized state. This is the world’s first drug-eluting bioresorbable stent and the plan is to slowly roll it out in Europe starting in a limited number of institutions and aiming for a full release toward the end of 2012.

Abbott Gets EU OK for Worlds First Bioresorbable Drug Eluting Stent

ABSORB is made of polylactide, a proven biocompatible material that is commonly used in medical implants such as resorbable sutures. Since a permanent metallic implant is not left behind, a patient’s vessel treated with ABSORB may ultimately have the ability to move, flex and pulsate similar to an untreated vessel. Restoration of these naturally occurring vessel functions, or vascular restoration therapy (VRT), is one of the features that makes ABSORB a significant innovation for patients in the treatment of coronary artery disease. In addition, continuing research indicates that the need to administer long-term dual anti-platelet therapy to patients may be reduced because the temporary scaffold is completely resorbed.

CE Mark approval for ABSORB in Europe was supported by data from the ABSORB clinical trials, which included patient follow-up out to three years. To further study the device in an expanded population, Abbott plans to initiate a randomized, controlled clinical trial in Europe later this year. The study will enroll approximately 500 patients at 40 centers throughout Europe and will compare ABSORB to Abbott’s XIENCE PRIME, which, together with XIENCE V, is the market-leading drug eluting stent system in Europe. The trial will provide additional data to support European commercialization and reimbursement activities. A global trial, including the U.S. and other geographies, is planned for later this year.

Source : http://www.abbott.com/news-media/press-releases/abbott-announces-international-launch-of-the-absorb-bioresorbable-vascular-scaffold.htm

Full story

Hip arthroscopy system launched by DePuy Mitek

Hip arthroscopy system launched by DePuy Mitek

Hip arthroscopy system launched by DePuy Mitek

DePuy Mitek, Inc., a leading developer and manufacturer of orthopaedic sports medicine products and soft tissue repair devices, announced the launch of ENDURANCE Hip Solutions, a new system of instruments and devices that marks the company’s entry into the rapidly growing field of hip arthroscopy.

DePuy Mitek-ENDURANCE Hip Solutions-Hip Exploded Tray

The announcement was made here at the 4th International Society for Hip Arthroscopy (ISHA) Annual Scientific Meeting where DePuy Mitek is showcasing its portfolio of devices and products for soft tissue repair in the hip, knee and shoulder.

“With ENDURANCE Hip Solutions, we’ve leveraged our clinical expertise and track record in soft tissue repair of the shoulder and knee to create a procedural hip arthroscopy solution from joint access to tissue and suture management,” said Ian Lawson, Worldwide President, DePuy Mitek.

ENDURANCE Hip Solutions includes stainless steel needles; nitinol guidewires and cannulas for access; suture anchors (GRYPHON™ Suture Anchor) in either BIOCRYL® RAPIDE™ biocomposite material or PEEK for fixation; and devices for tissue ablation (VAPR® VUE™ Radiofrequency System) and fluid management (FMS DUO®+). DePuy Mitek will sponsor education and training on hip arthroscopy and the new system throughout the country.

“The combination of trusted devices, sutures and materials that have proven successful in shoulder and knee arthroscopic surgery with new specialized instrumentation and tools, provides a welcome new solution for hip arthroscopy,” said Carlos Guanche, MD,* Southern California Orthopedic Institute in Van Nuys.

According to industry estimates, more than 30,000 hip arthroscopy procedures were performed in 2008 and were projected to grow annually at over 15 percent through 2013.(1) Hip arthroscopy is used to relieve pain caused by femoracetabular impingement resulting in damage to the labrum, articular cartilage or other soft tissue surrounding the hip.

The use of an arthroscope enables surgeons to see and navigate deep inside the joint without the need for large incisions and major disruption to surrounding tissue and muscle. This technique may lead to a quicker and less painful recovery and a faster return to activity than traditional surgery.(2)

“We expect that improvements in technology, more opportunities for surgeon education and training and rising patient demand will fuel increased adoption of hip arthroscopy,” added Lawson.

Key Components of ENDURANCE Hip Solutions

Hip Access Kit: Comprehensive set including needles and nitinol guidewires for initial joint entry

GRYPHON Anchor with Hip Drill Guide: Available in BIOCRYL RAPIDE Biocomposite Material or PEEK. Loaded with ORTHOCORD® HIGH-STRENGTH Orthopaedic Suture

Clear Cannulas: Available in 90 mm and 110 mm, which offers access to the deeper hip joint while maintaining visibility of tools

FMS DUO+ System: Enables optimal visibility by managing both inflow and outflow; reduces risk of extravasation in hip arthroscopy through independent control of pressure and flow

VAPR VUE Radiofrequency System: System with COOLPULSE® Technology enables 20.4 percent faster ablation than leading competitor at equal or lower heat levels (3)

About DePuy Mitek, Inc.

DePuy Mitek, Inc. is a global leader in orthopaedic sports medicine devices and products used in the treatment of joint injuries related to sports and physical activity. The company’s portfolio includes minimally invasive arthroscopic solutions and non surgical therapies to help patients move beyond joint injuries and pain. DePuy Mitek is part of DePuy Synthes Companies of Johnson & Johnson, the largest provider of orthopaedic and neurological solutions in the world. Visit, www.depuysynthes.com for more information.

Source : http://www.news-medical.net/news/20120928/Hip-arthroscopy-system-launched-by-DePuy-Mitek.aspx

Related Posts Plugin for WordPress, Blogger...

Full story

Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes